Nektar Therapeutics NKTR R3KPHARMA

Q: What is the current share price of Nektar Therapeutics (NKTR)?

As of 2026-09-19 21:16 PDT, Nektar Therapeutics (NKTR) trades at $75.44 on NasdaqCM. Its 52-week range is $25.72 to $100.35.

Q: What is the market capitalisation of NKTR?

Nektar Therapeutics (NKTR) has a market capitalisation of $2.58B on NasdaqCM.

Q: What is the P/E ratio of NKTR?

NKTR trades at a trailing price-to-earnings (P/E) ratio of -12.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.54.

Q: What is the return on equity (ROE) of NKTR?

NKTR has a return on equity (ROE) of -35.76%. Its return on capital employed (ROCE) is -57.64%.

Q: Is NKTR a good stock to buy?

This page provides a data-driven analysis of Nektar Therapeutics (NKTR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.nektar.com

Company Profile ↓

$75.44

+193.31% 1Y

Mkt Cap$2.58B

P/E-12.33

P/B2.54

52W High$100.35

52W Low$25.72

Book Value$26.46

EPS (TTM)$-6.12

Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Recent Developments

Dec 2025 Revenue of $55.23M (-43.9% YoY); net profit $-164.08M.
Trailing 12 Months Year-on-year growth — revenue -9.3%.
5-Year Trend Long-term compounding — revenue CAGR -1.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-1.75%
1 Year:	-9.30%

Stock Price Performance

1 Year:	+193.31%
6 Months:	+9.10%
3 Months:	+33.24%
1 Month:	-1.36%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 67% of range

$25.72 $100.35

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)56.00 · Neutral

Price Performance

1M-1.36%

3M+33.24%

6M+9.10%

1Y+193.31%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -1.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-12.33

Industry PE

24.83

Forward P/E

-6.96

PEG Ratio

0.31

Book Value

$26.46

Price to Book

2.54

P/S

41.97

EV/EBITDA

-13.74

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-1.75%

Profit 5Y

Revenue (YoY)

-9.30%

Earnings (YoY)

Profitability & Returns

ROCE

-57.64%

ROE

-35.76%

ROA

-12.54%

Profit Margin

Op Margin

Gross Margin

100.00%

EPS (Latest Qtr)

$-1.82

EPS (TTM)

$-6.12

Balance Sheet & Liquidity

Debt/Equity

0.15

Quick Ratio

9.71

Current Ratio

10.42

Debt

$135.93M

Total Assets

$763.27M

Current Assets

$589.04M

Working Capital

$212.73M

Ownership

Promoter Holding

0.35%

Chg in Prom Hold

-0.10%

FII / Inst Holding

106.44%

Chg in FII Hold

0.07%

Financial Snapshot

Enterprise Value

$2.58B

Total Revenue (TTM)

$54.59M

EBITDA

$-129.95M

Free Cash Flow

$-134.77M

Operating Cash Flow

$-233.79M

Shares Outstanding

34.14M

Gross Margin

100.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NKTR Nektar Therapeutics R3KPHARMA	75.44	-12.33	$2.58B	0.00%	-57.64%	-35.76%	-1.75%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	24.73M	34.59M	152.93M	95.47M	38.02M	1.09B	27.76M	39.83M	28.22M	23.32M	29.22M	33.86M	50.57M	48.85M	30.03M	23.46M	23.65M	28.33M	24.92M	25.01M	24.82M	21.59M	23.62M	21.59M	20.50M	24.14M	21.64M	23.49M	24.12M	-	10.46M	11.18M	11.79M	21.81M	10.86M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.98M	0	0	0	0	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.20M	10.46M	11.18M	11.79M	21.81M	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54.83M	46.96M	43.32M	40.90M	49.12M
Operating Income	-29.36M	-9.48M	-38.33M	-32.90M	-32.15M	-54.44M	-50.66M	69.48M	-24.03M	-86.74M	973.60M	-98.63M	-100.30M	-120.69M	-110.97M	-98.74M	-109.64M	-133.63M	-77.71M	-103.05M	-110.72M	-109.39M	-110.20M	-113.60M	-112.91M	-116.56M	-152.84M	-54.30M	-134.71M	-50.60M	-44.86M	-35.43M	-49.77M	-34.34M	-	-44.37M	-35.78M	-31.53M	-19.09M	-38.26M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-40.97M	-33.79M	-28.78M	-24.74M	-35.00M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.97M	5.39M	6.05M	9.77M	7.94M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-46.37M	-39.40M	-35.02M	-34.70M	-43.09M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	52.00K	-188.00K	-33.00K	31.00K	64.00K
Net Income	-54.14M	-19.50M	-48.60M	-43.22M	-42.20M	-63.87M	-59.87M	60.87M	-33.83M	-95.79M	971.46M	-96.14M	-98.21M	-119.63M	-110.29M	-98.58M	-112.16M	-138.65M	-80.00M	-108.59M	-117.20M	-122.97M	-125.52M	-129.71M	-145.65M	-90.39M	-159.07M	-59.05M	-137.02M	-51.12M	-45.84M	-36.80M	-52.36M	-37.06M	-	-50.88M	-41.59M	-35.52M	-36.08M	-44.90M
Diluted EPS	-0.40	-0.14	-0.36	-0.32	-0.28	-0.42	-0.39	0.37	-0.21	-0.60	5.33	-0.56	-0.57	-0.69	-0.63	-0.56	-0.64	-0.78	-0.45	-0.61	-0.65	-0.68	-0.69	-0.70	-790.00	-0.49	-0.85	-0.31	-0.73	-0.27	-0.24	-0.19	-3.76	-2.66	-	-3.60	-2.95	-1.87	-1.78	-1.82
R&D Expense	47.13M	49.27M	52.35M	51.95M	50.23M	61.06M	60.26M	65.71M	81.43M	99.42M	88.33M	102.89M	108.88M	118.46M	106.69M	99.05M	110.37M	108.99M	96.44M	100.53M	102.72M	95.60M	101.31M	103.74M	99.61M	107.25M	42.74M	33.59M	30.47M	29.68M	24.07M	27.41M	29.72M	35.03M	-	30.48M	29.89M	27.25M	-	35.68M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	71.93M	159.04M	71.48M	81.19M	148.92M	200.71M	230.78M	165.44M	307.71M	1.19B	114.62M	152.91M	-	92.06M	90.12M	98.43M	55.23M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	21.64M	33.77M	30.69M	0
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	70.42M	56.35M	67.74M	55.23M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	310.66M	191.58M	197.66M	186.00M
Operating Income	-95.13M	-28.25M	-123.94M	-141.20M	-120.13M	-16.48M	-29.37M	-112.86M	-59.64M	687.93M	-440.04M	-425.11M	-	-240.24M	-135.22M	-129.92M	-130.77M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-323.04M	-243.11M	-86.70M	-128.28M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	28.91M	25.33M	28.11M	26.18M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-364.98M	-276.26M	-119.20M	-155.49M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	3.21M	-200.00K	-239.00K	-138.00K
Net Income	-102.52M	-37.94M	-133.98M	-171.85M	-162.01M	-53.92M	-81.18M	-153.52M	-96.69M	681.31M	-440.67M	-444.44M	-	-368.20M	-276.06M	-118.96M	-164.08M
Diluted EPS	-	-	-	-	-	-	-	-1.10	-0.62	3.78	-2.52	-2.49	-	-29.55	-21.75	-8.70	-9.73
R&D Expense	95.11M	108.06M	126.77M	148.68M	190.01M	147.73M	182.79M	203.80M	268.46M	399.54M	434.57M	408.68M	400.27M	218.32M	114.16M	120.91M	117.33M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	521.23M	606.55M	497.79M	434.53M	441.62M	498.64M	568.87M	508.87M	2.15B	1.98B	1.54B	-	710.60M	398.03M	303.85M	280.41M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	545.97M	330.70M	261.29M	266.27M
Cash & Equivalents	155.58M	49.60M	17.75M	15.31M	25.44M	39.07M	12.37M	55.57M	59.64M	4.76M	194.91M	96.36M	198.96M	-	88.23M	35.28M	44.25M	15.12M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	15.80M	19.20M	16.10M	0	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	22.49M	5.98M	1.21M	0	-
Total Liabilities	-	-	430.56M	408.74M	450.77M	524.43M	405.29M	492.21M	480.75M	421.04M	432.60M	571.97M	461.47M	-	343.96M	267.05M	243.11M	190.57M
Current Liabilities	-	-	64.11M	275.53M	78.54M	98.22M	64.05M	61.25M	72.22M	56.16M	82.00M	353.89M	115.78M	-	68.20M	51.27M	61.40M	53.54M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	131.50M	117.78M	102.56M	85.75M
Total Equity	190.15M	102.37M	90.66M	197.81M	47.02M	-89.90M	36.33M	6.43M	88.12M	87.83M	1.72B	1.41B	1.08B	-	366.64M	130.99M	60.74M	89.83M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.57M	12.76M	12.94M	20.38M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	39.74M	-55.87M	-113.74M	-129.76M	-38.53M	-	-	-117.02M	-80.41M	718.21M	-328.68M	-313.29M	-	-304.01M	-192.61M	-175.71M	-208.51M
Investing Cash Flow	-149.03M	16.71M	-111.95M	113.02M	49.91M	-	-	-82.40M	-28.81M	-1.38B	206.89M	496.21M	-	365.83M	139.56M	142.57M	-1.20M
Financing Cash Flow	3.54M	7.54M	222.34M	26.80M	2.22M	-	-	203.62M	54.39M	851.97M	23.36M	-80.35M	-	1.51M	30.00K	42.12M	180.57M
Capital Expenditure	-16.39M	-31.46M	-9.72M	-10.58M	-4.09M	-9.98M	-11.20M	-6.39M	-9.68M	-14.24M	-26.29M	-7.26M	-	-5.68M	-865.00K	-1.47M	-171.00K
Free Cash Flow	23.35M	-87.33M	-123.46M	-140.34M	-42.62M	-	-	-123.42M	-90.09M	703.98M	-354.97M	-320.55M	-	-309.68M	-193.47M	-177.18M	-208.68M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	63.34M	-53.01M	8.98M	-29.14M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3.00M	0

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	76.5%	62.5%	68.8%	100.0%
Operating Margin %	-132.3%	-17.8%	-173.4%	-173.9%	-80.7%	-8.2%	-12.7%	-68.2%	-19.4%	57.6%	-383.9%	-278.0%	-	-261.0%	-150.0%	-132.0%	-236.8%
Net Margin %	-142.5%	-23.9%	-187.4%	-211.7%	-108.8%	-26.9%	-35.2%	-92.8%	-31.4%	57.1%	-384.5%	-290.6%	-	-400.0%	-306.3%	-120.9%	-297.1%
ROE %	-100.1%	-41.8%	-67.7%	-365.5%	180.2%	-148.4%	-1,262.7%	-174.2%	-110.1%	39.7%	-31.4%	-41.3%	-	-100.4%	-210.8%	-195.9%	-182.6%
ROCE %	-	-6.2%	-37.4%	-33.7%	-35.7%	-4.4%	-6.7%	-22.7%	-13.2%	33.3%	-27.1%	-29.9%	-	-37.4%	-39.0%	-53.6%	-57.6%

Shareholding Pattern

Insiders

0.35%

Institutions

106.44%

Public Float

106.81%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	14.84%	5.07M	$340.06M
2	Two Seas Capital Lp	9.06%	3.09M	$207.49M
3	Blackrock Inc.	8.62%	2.94M	$197.40M
4	BVF Inc.	7.00%	2.39M	$160.44M
5	Vanguard Capital Management LLC	4.38%	1.50M	$100.44M
6	Two Sigma Investments, LP	3.52%	1.20M	$80.65M
7	Vestal Point Capital, LP	2.93%	1.00M	$67.10M
8	Morgan Stanley	2.74%	936.56K	$62.84M
9	State Street Corporation	2.66%	909.68K	$61.04M
10	Geode Capital Management, LLC	2.58%	881.31K	$59.14M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NKTR

Google News Sun, 06 Sep 2026

Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdllFTzJxcTVPV1B2aS1QMkpQNmlWeDhmdEk0NnVHWFVLVWk3cktmNzg2OFNVV2NiNHFmMllSTFNYcFhRbnFGaDhCSUdsTlFSNVYtVlRjWE5PLUtCc2pYa01Sa0xYQkJrdzJEWS1lR0N4U2l5NFh0eDZfdWZRZE8wLTlicXhKajlLN0xvS3…

Google News hu, 07 May 2026

Nektar Therapeutics Reports First Quarter 2026 Financial Results - PR Newswire

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOSDlBMThOblhhdDQ0TjRJRlVmeW1vT0hkcm9sbWd0MTlLWlJYY1hobjBQNkpRa2otWUZUSTFTWVlqRE95bnBqcUdzdDE2RE43aVhPTTRCZ2ZyaGwtY3BSZDBQdHVBVUN1ZS13RWVuQ2o1UkVVNFZRVDlzeUE4ZXZSZ01hU29TUzJvU0xQVn…

Google News Mon, 07 Sep 2026

Precision Trading with NKTR Corp (NKTR) Risk Zones - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQMDJCREw3ZllMU1I0eS1mQ2ZQZkhENW4wcGNBcXVGSnpDaWtYdDRDVDFXWjN5Y1Y3alp3dFlyeklLNThJMVZEWFpvdEdoU0pEMlZuU29LN3o3NWtwVzY5ZWpoMWNyalpUZHo2MldBZ3MyTTcySTN4X3FKOVExLUFoR1NFcF94MElvOWtGY0…

Google News ue, 12 May 2026

Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPMi1lRFNqTWVORjJCSmY1QlFPcUJLelRVY2JGaFVlZDI2THA3ekZJUlc5cEFBXzVIUnJwMDVlbVJiVU5tWHpPVVhtS1hlTE5nM2Y1WHBkUXVDT0hFTnVUMEkyZW9mWjBOYmFiQ25qR3ViUVI2WUY5eEFhZXpqQnE2eHpyS25IXy1hVDdWUV…

Google News hu, 05 Mar 2026

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNaXVwNTZnNWVaS3pibHFEbnNjZWhvSGd2TUtpU2YyRERocTR1SWwwUWVkX3RiaVpobW5WYjR6S01VWEw2eTU0MERPQmpyU2FOaEYyY0VZWHhCSkxaeTNnV1hESnM3SG94YXRtXzBNd0k2d01HYmphSHQxdWQ5MVB1dTJJRW1sVXZaSzBCd3…

Google News Mon, 24 Aug 2026

$NKTR stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQYjBaYk5kWWd5SjBKUkY5YmFHUWlLSHlwSzFvU0RCUm1MaG41X1o5aWpVNVNabXUwdHU0YlgwRkhlNXZzUmN2bWFKd3JQWE83UVdmS2c0ZC1tREZZUy12SWZzRXBweld5NkU0aURvdWlnLWNlR2wxWnI1VVBKSFVxZ2IyUHBiM1ZFRDNSaG…

NKTR — Frequently Asked Questions

What is the current share price of Nektar Therapeutics (NKTR)?

As of 2026-09-19 21:16 PDT, Nektar Therapeutics (NKTR) trades at $75.44 on NasdaqCM. Its 52-week range is $25.72 to $100.35.

What is the market capitalisation of NKTR?

Nektar Therapeutics (NKTR) has a market capitalisation of $2.58B on NasdaqCM.

What is the P/E ratio of NKTR?

NKTR trades at a trailing price-to-earnings (P/E) ratio of -12.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.54.

What is the return on equity (ROE) of NKTR?

NKTR has a return on equity (ROE) of -35.76%. Its return on capital employed (ROCE) is -57.64%.

Is NKTR a good stock to buy?

This page provides a data-driven analysis of Nektar Therapeutics (NKTR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Nektar Therapeutics NKTR R3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st

Nektar Therapeutics Reports First Quarter 2026 Financial Results - PR Newswire

Precision Trading with NKTR Corp (NKTR) Risk Zones - Stock Traders Daily

Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum - finance.yahoo.com

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits

$NKTR stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

NKTR — Frequently Asked Questions

What is the current share price of Nektar Therapeutics (NKTR)?

What is the market capitalisation of NKTR?

What is the P/E ratio of NKTR?

What is the return on equity (ROE) of NKTR?

Is NKTR a good stock to buy?

Explore More